TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2876024

Group type: EXPERIMENTAL
Intervention: Gastric ulcer follow-up after an average of 21.2 months
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Duodenal ulcer follow-up after an average of 35.6 months
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Asymptomatic recurrences in gastric and duodenal ulcers
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Effect of smoking on recurrence rates
Number of subjects: 110
Study: 28110590

Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial rupture of membranes when cervical dilation was at 3 cm)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard amniotomy (membranes left to rupture spontaneously)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard amniotomy
Number of subjects: 200
Study: 27058753

Group type: EXPERIMENTAL
Intervention: GEM plus S-1 (GEM-S-1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: GEM
Number of subjects: 75

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CA19-9<466 U/ml
Number of subjects: 75

Group type: COMPARATOR
Intervention: CA19-9>571 U/ml
Number of subjects: 75
Study: 24156957

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 750

Group type: COMPARATOR
Intervention: Clomiphene
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Men's characteristics
Number of subjects: 750
Study: 22770683

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (medical treatment)
Number of subjects: 75
Study: 20043983

Group type: EXPERIMENTAL
Intervention: Endotoxin (inflammatory challenge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17726317

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Incomplete revascularization
Number of subjects: 790
Study: 15848983

Group type: EXPERIMENTAL
Intervention: Moisturizer containing urea applied twice daily for 20 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (other forearm without moisturizer)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patch tests with 0%, 0.5% and 2% NiSO4 in petrolatum
Number of subjects: 30
Study: 12877666

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2.25 microg/kg, s.c., once weekly for 12 weeks
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344
Study: 11895470

Group type: EXPERIMENTAL
Intervention: Alcohol (3 units of ethanol daily for 1 week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No alcohol (abstinence for 1 week)
Number of subjects: 21
Study: 9821922

Group type: EXPERIMENTAL
Intervention: Subperiosteal dissection without release
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Subperiosteal dissection with release
Number of subjects: 8

Group type: COMPARATOR
Intervention: Subgaleal dissection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All dissection methods
Number of subjects: 8
Study: 7907261

Group type: EXPERIMENTAL
Intervention: FSH (150 IU twice a week for 2 weeks, then 150 IU FSH and 250 IU hCG twice a week for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: hCG (250 IU twice a week for 6 weeks)
Number of subjects: 22
Study: 2644151

Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms t.i.d. for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide (both dosages)
Number of subjects: 12
Study: 31093742

Group type: EXPERIMENTAL
Intervention: ProTaper retreatment instruments in combination with gutta‐percha solvent
Number of subjects: 90

Group type: COMPARATOR
Intervention: ProTaper retreatment instruments without solvent
Number of subjects: 90
Study: 31619767

Group type: EXPERIMENTAL
Intervention: EBV transformed B cells
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: CD40L-activated B cells
Number of subjects: 3
Study: 29165767

Group type: EXPERIMENTAL
Intervention: LMA insertion anesthesia
Number of subjects: 76

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 76
Study: 25939678

Group type: EXPERIMENTAL
Intervention: 4% topical glycopyrrolate wipes
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2% topical glycopyrrolate wipes
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 36
Study: 23572499

Group type: EXPERIMENTAL
Intervention: AF±AFL ablation (n=182)
Number of subjects: 360

Group type: COMPARATOR
Intervention: AFL ablation only (n=178)
Number of subjects: 360
Study: 21705552

Group type: EXPERIMENTAL
Intervention: High hydrostatic pressure processing (HPP) at 600 MPa at 6°C for 5 min
Number of subjects: 44

Group type: COMPARATOR
Intervention: High hydrostatic pressure processing (HPP) at 400 MPa at 6°C or 25°C
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no HPP treatment)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Granulocyte shift in infected subjects
Number of subjects: 44
Study: 19379093

Group type: EXPERIMENTAL
Intervention: Mood stabilizers (except divalproic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalproic acid and carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole (an antipsychotic)
Number of subjects: 0
Study: 16817288

Group type: EXPERIMENTAL
Intervention: Albumin and mannitol added to the pump prime (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heparin-coated perfusion system (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Leukocyte-depletion arterial line filter (Group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 36
Study: 12771320

Group type: EXPERIMENTAL
Intervention: Dietary plant sterol ester (PSE) at a dosage of 2.8 g/d (1.68 g/d phytosterols) for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dietary plant sterol ester (PSE) for II, IV, and VV phenotypes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (margarine without PSE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CETP concentration
Number of subjects: 60
Study: 10857945

Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5, 1.0, 2.0 mg in study 1 and 4.0 mg in study 2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9118656

Group type: EXPERIMENTAL
Intervention: Group B (1.5 g of amino acids/kg/day with 45% branch-chain amino acids)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Group C (1.1 g/kg/day of amino acids with 45% branch-chain amino acids)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Group A (1.5 g of amino acids/kg/day with 23% branch-chain amino acids)
Number of subjects: 69
Study: 8175200

Group type: EXPERIMENTAL
Intervention: Duraflo II
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 29551231

Group type: EXPERIMENTAL
Intervention: Once per week (QW) SBRT, 40 Gy in 5 fractions
Number of subjects: 152

Group type: COMPARATOR
Intervention: Every other day (EOD) SBRT, 40 Gy in 5 fractions
Number of subjects: 152
Study: 26718095

Group type: EXPERIMENTAL
Intervention: Physician manager-centered hypertension management intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 102
Study: 24809759

Group type: EXPERIMENTAL
Intervention: Asthma APGAR system
Number of subjects: 468

Group type: COMPARATOR
Intervention: ACT™/CACT™
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Controller medications
Number of subjects: 468
Study: 22289123

Group type: EXPERIMENTAL
Intervention: New road tunnel intervention
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Passive samplers for NO(2)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Land use regression model (LUR)
Number of subjects: 4
Study: 20099203

Group type: EXPERIMENTAL
Intervention: EFTT with imaginal confrontation (IC)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EFTT with empathic exploration (EE)
Number of subjects: 45
Study: 18598735

Group type: EXPERIMENTAL
Intervention: Sertraline (100-200 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluoxetine (40-80 mg/day)
Number of subjects: 42
Study: 15796627

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 0
Study: 12091330

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: PBSCT
Number of subjects: 126

Group type: COMPARATOR
Intervention: BMT
Number of subjects: 126
Study: 10320602

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (1.0 ml x kg(‐1))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (1.0 ml x kg(‐1))
Number of subjects: 80
Study: 7853584

Group type: EXPERIMENTAL
Intervention: 3 cycles of 100 mg/m2 neoadjuvant cisplatin before radical cystectomy (arm B)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group treated only with radical cystectomy (arm A)
Number of subjects: 122
Study: 1826253

Group type: EXPERIMENTAL
Intervention: prazosin (alpha 1-adrenergic blocker)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: atenolol (cardioselective beta-adrenergic blocker)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: carteolol (nonselective beta-adrenergic blocker)
Number of subjects: 26
Study: 7036354

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nafcillin or Methicillin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clindamycin (IV therapy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nafcillin/Methicillin (IV therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clindamycin (oral therapy)
Number of subjects: 25
Study: 30794658

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice a day for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (200 mg twice a day for 7 days)
Number of subjects: 40
Study: 29793488

Group type: COMPARATOR
Intervention: Normolip 5 (N)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Argicolina (A)
Number of subjects: 20
Study: 26739737

Group type: EXPERIMENTAL
Intervention: 20 mL of physiological saline by an intrauterine catheter
Number of subjects: 192

Group type: COMPARATOR
Intervention: 10 mL of saline intravaginally
Number of subjects: 192
Study: 24503560

Group type: EXPERIMENTAL
Intervention: Group B (80 kV, 600 mAs, 50% reduction in contrast medium dose)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group A (120 kV, 400 mAs)
Number of subjects: 84
Study: 22147447

Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m² weekly), 5-fluorouracil (250 mg/m² for 5 days/week), pelvic radiation (45 Gy/1.8 Gy/fraction for 5 days/week)
Number of subjects: 36
Study: 19021619

Group type: EXPERIMENTAL
Intervention: Intravesical alkalinized lidocaine (PSD597) 200 mg lidocaine, alkalinized with 8.4% sodium bicarbonate solution, for 5 consecutive days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 17999405

Group type: EXPERIMENTAL
Intervention: 5-session family intervention
Number of subjects: 235

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 235
Study: 15121020

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1 mg ibandronate
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 11777712

Group type: EXPERIMENTAL
Intervention: Stop-and-chop technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Phaco-out technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 30
Study: 9844703

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution with 37.5 micrograms epinephrine (group C + E)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Epidural anesthesia with 150 micrograms clonidine in 15 ml bupivacaine 0.25% solution without epinephrine (group C)
Number of subjects: 44
Study: 8088613

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous bone marrow support (ABMS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimens with ABMS (cyclophosphamide, cisplatin, thiotepa or cyclophosphamide, carboplatin, mitoxantrone)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-dose salvage chemotherapy
Number of subjects: 200
Study: 2684006

Group type: EXPERIMENTAL
Intervention: Tetracycline (1 g)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Furazolidone (400 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 4317858

Group type: EXPERIMENTAL
Intervention: 780 SE (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenfluramine (40 mg)
Number of subjects: 0
Study: 31806947

Group type: EXPERIMENTAL
Intervention: Mobile Geriatric Team (MGT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 29247112

Group type: EXPERIMENTAL
Intervention: Conservative SpO2 target of 88%-92%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Liberal SpO2 target of >94%
Number of subjects: 120
Study: 25567555

Group type: EXPERIMENTAL
Intervention: Guanfacine (up to 3 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24317185

Group type: EXPERIMENTAL
Intervention: Treadmill walking for 20 min at aerobic levels
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attentional control group watching a video
Number of subjects: 20
Study: 21947207

Group type: EXPERIMENTAL
Intervention: Plant stanols (8.8 g/day for 10 weeks, followed by 4.5 g at breakfast)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plant stanols (4.5 g at breakfast)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plant stanols (8.8 g/day for 10 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no plant stanols)
Number of subjects: 38
Study: 18840641

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 150 mg/month (n = 47)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (n = 46)
Number of subjects: 93
Study: 17727401

Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no bispectral index monitoring)
Number of subjects: 50
Study: 16216961

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12114358

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 44
Study: 10222636

Group type: EXPERIMENTAL
Intervention: Psychoeducational-nursing intervention using the Progressively Lowered Stress Threshold (PLST) model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine information and referrals for case management, community-based services, and support groups
Number of subjects: 0
Study: 7838507

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 100
Study: 2365760

Group type: EXPERIMENTAL
Intervention: Advice booklet and support visits
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Booklet only
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: No intervention
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-night waking infants (comparison group)
Number of subjects: 3
Study: 221871

Group type: EXPERIMENTAL
Intervention: High-dose conjugated estrogens with cyclic progesterone
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 168
Study: 31521520

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: PDRN injection
Number of subjects: 44
Study: 31484712

Group type: EXPERIMENTAL
Intervention: Inosine (titrated to produce mild or moderate serum urate elevation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inosine (mild or moderate dosing)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inosine (higher dosing)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 27955995

Group type: EXPERIMENTAL
Intervention: AADvac1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26549785

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Glycopyrronium bromide 50 μg
Number of subjects: 37
Study: 23362890

Group type: EXPERIMENTAL
Intervention: Clonidine 50 µg (Group C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 µg (Group D)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.5% 3 ml + saline 0.5 ml (Group B)
Number of subjects: 90
Study: 20933337

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 77
Study: 19528362

Group type: EXPERIMENTAL
Intervention: Augmented volume removal therapy
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Observational cohort of 37 patients
Number of subjects: 145
Study: 16732778

Group type: EXPERIMENTAL
Intervention: Live music therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Recorded music therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: No music therapy
Number of subjects: 31
Study: 14617526

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study: 10066844

Group type: EXPERIMENTAL
Intervention: Licostinel (0.03 to 3.0 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7726818

Group type: EXPERIMENTAL
Intervention: Self-reinforcement
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined effects of methylphenidate and self-reinforcement
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.7 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Drug placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Noncontingent reinforcers
Number of subjects: 6
Study: 2252187

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6102838

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic receptor blocking therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (no beta-blocker therapy)
Number of subjects: 183
Study: 30763396

Group type: EXPERIMENTAL
Intervention: Cognitive-affective symptoms
Number of subjects: 568
Study: 27933720

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafting
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-grafting (control)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups (test and control)
Number of subjects: 51
Study: 24314348

Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control subjects (placebo)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heroin and Saline (both groups)
Number of subjects: 22
Study: 23155432

Group type: EXPERIMENTAL
Intervention: Early insertion (day 5-9 after mifepristone)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Delayed insertion (at 3-4 weeks after mifepristone)
Number of subjects: 129
Study: 20147617

Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein 2b/3a (GP2b/3a) antagonists
Number of subjects: 81918

Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 81918

Group type: COMPARATOR
Intervention: Control group (assumed 3% major bleeding rate)
Number of subjects: 81918

Group type: COMPARATOR
Intervention: Active-controlled thienopyridine trial
Number of subjects: 81918
Study: 17373923

Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient (HVPG) measurement
Number of subjects: 60

Group type: COMPARATOR
Intervention: HVPG <or= 22 mmHg
Number of subjects: 60

Group type: COMPARATOR
Intervention: HVPG > 22 mmHg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Encephalopathy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Model for End‐Stage Liver Disease (MELD) score > 25
Number of subjects: 60
Study: 15998891

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU on alternate days)
Number of subjects: 39876
Study: 12490017

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of antibiotic (200 mg of ofloxacin) during anesthetic induction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment doses of antibiotic (400 mg of ofloxacin per day) until the nephrostomy catheter was removed
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both groups (single-dose vs short-course)
Number of subjects: 81
Study: 10023700

Group type: EXPERIMENTAL
Intervention: EORTC Quality of Life Questionnaire
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: EORTC pain subscale
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Overall QOL
Number of subjects: 206
Study: 7502282

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 98
Study: 2311806

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 97

Group type: COMPARATOR
Intervention: Parenteral pethidine
Number of subjects: 97